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Abstract
Purpose Nasopharyngeal carcinomas (NPC) are radio-
sensitive, and radiotherapy is the standard curative treat-
ment. Furthermore, it has been shown that combined
radiochemotherapy improves prognosis in locally advanced
stages. Further encouraging results have been obtained with
adjuvant interferon-beta after primary radio(chemo)therapy
in childhood undifferentiated NPC. Aim of the present
study was to evaluate the treatment results after long-term
follow-up after radio(chemo)therapy for adult NPC with
special reference to patients with undifferentiated carcino-
mas treated with adjuvant interferon-beta.
Patients and methods From 02/1992 to 07/2008, 26 adult
patients with NPC without distant metastases were treated
(17 squamous cell carcinomas, 9 undifferentiated carcino-
mas). The treatment concepts changed over the years: 13
patients were treated with radiotherapy alone, 13 patients
received combined radiochemotherapy. Additionally, six
patients with undifferentiated carcinomas were treated
with adjuvant interferon-beta after radiochemotherapy for
6 months.
Results After a median follow-up of 96 months, 17
patients remain alive. Collectively, our 5-year overall-
survival and loco-regional control rates were 74% (radio-
chemotherapy 81%, radiotherapy alone 68.5%) and 87%
(radiochemotherapy 100%, radiotherapy alone 72.7%),
respectively. All treatment regimens used were feasible;
especially, adjuvant interferon-beta was applied as pro-
vided without high grade toxicity. All patients with
undifferentiated carcinomas treated with adjuvant inter-
feron-beta stayed alive until the end of the follow-up.
Conclusion In summary, our data afﬁrm that NPC in
adults are curable by primary radio(chemo)therapy. Fur-
thermore, our data indicate that adjuvant interferon-beta
application in undifferentiated NPC in adults is feasible
and shows promising results. Further prospective clinical
trials are needed to ﬁnally establish adjuvant interferon
beta in curative treatment of adult NPC.
Keywords Nasopharyngeal carcinoma  Interferon-beta 
Radiochemotherapy  EBV
Introduction
The nasopharyngeal carcinoma (NPC) evolves from the
epithelial cells in the nasopharynx (Jeyakumar et al. 2006).
A distinction is drawn between three different histological
subgroups: keratinizing squamous cell carcinoma, squa-
mous cell carcinoma without keratinizing, and undiffer-
entiated lymphoepithelial carcinoma (Brennan 2006).
Pathogenesis of the undifferentiated carcinoma is highly
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Barr virus (Chu et al. 2008). In some areas in South China,
the incidence of NPC is about 80 of 100,000 people and
NPC is a disease of the adult. Interestingly, in Western
civilisation the incidence with 1 of 100,000 is much lower,
but one-third of these patients are children (Licitra 2003).
70% of patients with NPC have to be classiﬁed in locally
advanced stages UICC III/IVA/B at the point of diagnosis
(Brennan 2006; Jeyakumar et al. 2006). Because of the
tumour location in the nasopharynx with possible inﬁltra-
tion in the base of the skull, a complete tumour resection in
curative intent is difﬁcult in many cases. Because of a
known distinctive sensitivity of nasopharyngeal carcino-
mas in radiotherapy, irradiation is recommended in the
curative treatment for NPC’s in the ﬁrst line (Lee et al.
1993), and especially undifferentiated NPC should not be
operated in principle. Thereby, radiotherapy alone was
gold standard in curative treatment of NPC until the early
1990s (Song et al. 2008). Since several studies showed that
in locally advanced carcinomas the combination of radio-
and chemotherapy (neoadjuvant and/or concomitant)
resulted in better treatment outcome than irradiation alone
(Baujat et al. 2006; Huncharek and Kupelnick 2002;
Langendijk et al. 2004; Yarney et al. 2008), the combina-
tion of radio- and chemotherapy became standard proce-
dure in the curative treatment of locally advanced (UICC
stages III/IVA/B) NPC’s in the late 1990s. However, the
optimum chemotherapy regimen for the neoadjuvant as
well as the concomitant chemotherapy has not been deﬁned
yet. Most of the reported schedules are cisplatin-based,
sometimes as monotherapy, sometimes in combination
with other agents like 5-FU or others (Chen et al. 2008;
M’Rabti et al. 2006; Ma and Chan 2005).
Another approach in the treatment of undifferentiated
NPC besides radio(chemo)therapy is an immunotherapy
with interferon-beta. First, it was used in the recurrent/
metastatic situation showing a good tumour response
(Dimery et al. 1989; Mahjoubi et al. 1993; Treuner et al.
1980). Because of the promising results of these reports,
Mertens et al. (1997) included an adjuvant immunotherapy
with interferon-beta application for 6 months after radio-
chemotherapy in children treated in curative intent with
radio- (UICC stage I/II) or radiochemotherapy (UICC stage
III/IV) in the NPC-91-GPOH trial (Nasopharynxkarzinom-
91-Gesellschaft fu ¨rP a ¨diatrische Onkologie und Ha ¨matol-
ogie) (Mertens et al. 1997, 2005). In this protocol, 59
children were treated as follows. One stage II patient
received irradiation as primary therapy. The other 58
patients received three courses of neoadjuvant chemother-
apy with methotrexate, cisplatin, and 5-FU followed by
radiotherapy. After irradiation, all patients were treated
with interferon-beta for 6 months. In summary, all patients
showed excellent local-regional control and overall
survival rates of 91 and 95% after 9 years, respectively
(Mertens et al. 2005). Based on these results, a consecutive
study for undifferentiated NPC in children started in 2003
(NPC-2003-GPOH; Nasopharynxkarzinom-2003-Gesell-
schaft fu ¨rP a ¨diatrische Onkologie und Ha ¨matologie) and is
recruiting until today. In this protocol, low-risk patients
(stage I or II) receive radiotherapy alone followed by
intravenous interferon-beta for 6 months. Patients stage III/
IVA/B receive three courses of neoadjuvant chemotherapy
with cisplatin, folinic acid, and 5-FU followed by con-
comitant radiochemotherapy with two courses of cisplatin
and adjuvant interferon-beta for 6 months.
Because of the encouraging results of the GPOH trials
investigating adjuvant interferon-beta in childhood NPC
treated with primary radiochemotherapy, we started to treat
adult patients with undifferentiated NPC according to the
GPOH-protocols with neoadjuvant chemotherapy, fol-
lowed by radio(chemo)therapy and adjuvant interferon-
beta at our department in 2001.
Aim of the present study was to analyse the outcome of
NPCs in adult patients during the last 17 years at our
institution with special regard to adjuvant interferon-beta in
undifferentiated carcinomas. Our data show in accordance
with the literature that adult patients with NPC can be
cured with radio(chemo)therapy alone without surgery.
Besides, all patients with undifferentiated carcinomas
treated with adjuvant interferon-beta according to the
GPOH-protocols are still alive. Based on the results of the
GPOH-studies in children and the present work, further
prospective trials are needed to establish the role of inter-
feron-beta in the curative treatment of adult NPC.
Patients and methods
Patients
Between February 1992 and July 2008, 26 adult patients
with carcinoma of the nasopharynx without distant
metastases were treated at our department in curative
intent. Patients were 21 males and 5 females. Patients’ age
ranged from 28 to 81 years (median 60 years). Disease was
staged according to the Union Internationale Contre le
Cancer/American Joint Committee on Cancer (UICC/
AJCC) criteria (Sobin and Wittekind 2002).
Two patients were in stage II, nine patients were in stage
III, and 15 patients were in stage IV. Thereby, in 2 patients
the primary tumour was staged as T1, in 6 patients as T2, in
5 patients as T3, and in 13 patients as T4. In summary, 20
patients presented with positive cervical lymph nodes (1
patient N1, 16 patients N2, and 3 patients N3). Tumours
were histologically determined as squamous cell carcinoma
with keratinisation in 4 patients (15%), as squamous cell
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123carcinoma without keratinisation in 13 patients (50%) and
as undifferentiated carcinoma in 9 patients (35%). 16
patients showed histological grade 2 and ten patients
showed grade 3. EBV-status in tumour biopsies before
radio(chemo)therapy was determined as follows: 17
patients were EBV positive, six negative, and in three
patients, status was missing because it was not determined
in the early 1990s, and there were no available histological-
blocs for retrospective analysis. Patient characteristics were
summarised in Table 1.
Pre-treatment examinations
Initial examinations before treatment included medical
history, clinical ENT (ear-nose-throat) examination (mag-
nifying laryngoscopy, upper bronchoscopy, esophagos-
copy, ear-nose-throat endoscopy) with biopsies in potential
mucosal primary sites, complete blood counts, biochemical
analysis, electrocardiogram, chest X-rays, abdominal
ultrasound, and CT scans of the thorax and the head and
neck with contrast medium. Whenever achievable a MRI
scan of the head and neck with contrast medium was car-
ried out. Pre-treatment characteristics of patients entered in
study are concluded in Table 1.
Treatment
In summary, due to changes in treatment protocols and
technical developments over the years, there are differ-
ences in cumulative dose, treatment techniques, and
accompanying therapies (chemotherapy, interferon-beta).
Details are summarised in Table 2.
Treatment monitoring and follow-up
Toxicity was monitored weekly during radio(chemo)ther-
apy and every second week following therapy until dis-
appearance of acute side effects. Subsequently, chronic
toxicity was monitored at least yearly for the ﬁrst 5 years
after radio(chemo)therapy. Side effects were classiﬁed
according to the CTC score for acute (Cox et al. 1995;
Trotti et al. 2000) and according to the LENT scoring
system for chronic side effects (Hendry et al. 2006; Rubin
et al. 1995).
After radiochemotherapy, remission was evaluated by
clinical ENT-examination (ear-nose-throat endoscopy,
magnifying laryngoscopy, whenever necessary upper bron-
choscopy, and esophagoscopy) and a computed tomography
with contrast medium. Complete remission was deﬁned as
the complete regression of all tumour manifestations.
Afterwards, patients underwent quarterly clinical ENT-
examination, complete blood counts, biochemical analysis,
chest X-rays, abdominal ultrasound or a computed tomog-
raphyoftheheadandneck,ifnecessary.Biopsiesweretaken
from suspect ﬁndings to receive histological conﬁrmation of
tumour growth.
Statistics
Survival probabilities were calculated from the day of
histological diagnosis. The Kaplan–Meier product-limit
method was used to determine overall survival and loco-
regional control. Loco-regional control was deﬁned as the
absence of local or regional recurrence or progression. The
possible impact of chemotherapy or EBV-status on prog-
nosis was estimated by univariate analysis (log-rank test).
Statistical analyses were generated with the programme
STATISTICA for windows version 6.1 [StatSoft, Inc.
(2002)].
Table 1 Pre-treatment characteristics of patients entered in the study
Characteristic No. of patients (%)
Gender
Male 21 (81)
Female 5 (19)
UICC stage
II 2 (8)
III 9 (34)
IV 15 (58)
T-Status
1 2 (8)
2 6 (23)
3 5 (19)
4 13 (50)
N-status
0 6 (23)
1 1 (4)
2 16 (62)
3 3 (11)
Histologic grade
2 16 (62)
3 10 (38)
EBV-Status in tumour
Positive 17 (65)
Negative 6 (23)
Not known 3 (12)
Interferon therapy
Yes 6 (23)
No 20 (77)
Concomitant chemotherapy
Yes 13 (50)
No 13 (50)
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123Results
After a median follow-up duration of 96 months (range 9–
198 months), 17 patients (65%) remained alive. Death has
occurred in nine patients (35%); while four of these died
from primary tumour, ﬁve died from intercurrent disease
[one-second primary (intracranial neuroblastoma), one
pulmonary embolism, one heart attack, and two not
known]. Collectively, the 5-year overall survival rate was
74% (life table analysis is shown in Fig. 1). Notably, all six
patients treated according to the GPOH protocols with
adjuvant interferon-beta are still alive until the end of the
follow-up.
Loco-regional relapse occurred in four patients (three
local, one regional); median time to relapse was 22 months
(range 6.4–36.8). Collectively, the 5-year loco-regional
control rate was 87%. One of the patients with loco-
regional relapse was treated according to the NPC-91-
GPOH protocol. In this patient, local relapse after
36.8 months was treated with salvage chemotherapy
because of inoperability in the year 2005. This patient was
still alive at the end of the follow-up without another
relapse after complete remission through salvage chemo-
therapy. The three other patients with loco-regional relapse
were squamous cell carcinomas and treated with concom-
itant radiochemotherapy. In the ﬁrst patient, local relapse
after 3 months was treated with salvage chemotherapy.
This patient died 6.4 months after salvage treatment
because of additional cervical metastases and general
constitution. In the second patient, radiochemotherapy after
macroscopic complete tumour resection was stopped on
demand of the patient because of severe acute side effects
after 28.8 Gy and one chemotherapy course. Local relapse
occurred 19 months after radiochemotherapy. As salvage
therapy, this patient underwent surgery and stayed alive
until the end of the follow-up. Regional relapse after
6.4 months in third patient was treated with salvage che-
motherapy. This patient died 2 months after the salvage
treatment because of the general constitution (loco-regional
control analysis is shown in Fig. 2).
Distant metastases occurred in two patients (one pul-
monary and one mediastinal). In one patient, a secondary
malignant tumour in the form of an intracranial neuro-
blastoma was recorded in 2004 after treatment of her NPC
in 1995. After chemotherapy this patient stayed alive until
the end of the follow-up without another relapse of the
neuroblastoma or the NPC.
Subgroup analyses concerning chemotherapy showed
better overall survival and loco-regional control rates for
radio(chemo)therapy compared to radiotherapy alone [81
vs. 68.5% (P = 0.54), and 100 vs. 72.7% (P = 0.072),
respectively]. However, the differences were not statisti-
cally signiﬁcant; this may be due to the small sample size.
Similarly, the EBV-status in the tumour biopsies before
radio(chemo)therapy had no impact on prognosis.
Toxicity
In summary, therapy was well tolerated. There were no
treatment-related deaths and no grade 4 toxicities. Grade 3
mucositis/dysphagia was seen in six patients. In an addi-
tional patient, grade 3 mucositis and skin reaction occurred.
Sole haematological toxicity in form of leukopenia Cgrade
3 appeared in two patients. In another two patients muco-
sitis/dysphagia and haematological toxicity Cgrade 3 (leu-
kopenia and anaemia or leukopenia alone) was observed.
Three of these patients received a concomitant radioche-
motherapy; the other one was treated with irradiation alone.
Fig. 1 Kaplan–Meier plot of overall survival for all patients, and for
patients with undifferentiated NPC treated with adjuvant IFN-beta,
calculated from the time of histopathological diagnosis
Fig. 2 Kaplan–Meier plot of loco-regional control for all patients,
and for patients with undifferentiated NPC treated with adjuvant IFN-
beta, calculated from the time of histopathological diagnosis
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123Thus, toxicity-related changes of the therapy schedule were
only infrequently necessary [one patient did not receive the
second of planned two courses cisplatin, one patient paused
7 days during a 5-FU and cisplatin chemotherapy, and
one patient missed two infusions of cisplatin 6 mg/
(m
2 TBSA day)]. Because of severe side effects (mucositis
and dysphagia), radiochemotherapy after macroscopic
complete tumour resection was stopped on demand of the
patient because of severe acute side effects after 28.8 Gy,
and one chemotherapy course (see above), in another
patient, the boost dose was reduced from 20 to 14 Gy
because of the dose at the organs at risk. In the six patients
treated with neoadjuvant chemotherapy according to the
GPOH-protocols, no side effects grade 2 or higher were
observed (one patient grade 1 anaemia and leukopenia
only). Adjuvant interferon-beta therapy was well tolerated
and could be applied regularly by all six treated patients.
Four patients developed fever during ﬁrst or second appli-
cation, but adapted on the therapy in following courses
without any further serious side effects. Late toxicity graded
C2 was recorded in ten patients (loss of taste: 4 patients;
loss of taste and xerostomia: three patients; xerostomia
alone: two patients; xerostomia, ﬁbrosis and lymph oedema:
one patient, ﬁbrosis did not signiﬁcantly impair quality of
life during follow-up). One of these patients was treated
with neoadjuvant chemotherapy, six with concomitant
radiochemotherapy and three with irradiation alone. There
was no ototoxicity assessed in our patient population.
Discussion
Our data conﬁrm the known fact that NPC can be cured by
radio(chemo)therapy and has a signiﬁcant better prognosis
compared to the other squamous cell head and neck cancer
entities (oral cavity, oropharynx, hypopharynx, larynx).
Thereby, our disease overall survival (74% after 5 years),
and loco-regional control rates (87% after 5 years) are
comparable to the literature (Table 3). Furthermore, to our
knowledge, we are the ﬁrst in literature to report the
treatment of adult NPC patients with radiochemotherapy
followed by adjuvant administration of interferon-beta
according to the GPOH protocols for childhood NPC
[NPC-1991 GPOH (Mertens et al. 2005; Mertens et al.
1997), NPC-2003 GPOH]. Our experiences show that this
regime is feasible without unacceptable toxicity in adult
patients. Furthermore, the fact that all our patients treated
with this regime are still alive at the end of our analysis is
encouraging and demand further prospective studies in this
ﬁeld.
However, the optimal radiochemotherapy schedule for
NPC has not been deﬁned yet. Besides good treatment
results obtained by concomitant radio(chemo)therapy, local
relapse is still a major problem (Daoud and Frikha 2001;
Lu 2004; O’Sullivan 2007; Yarney et al. 2008). One pos-
sibility to improve LRC, and thus OS, is dose escalation of
radiotherapy, and several authors propagate this in radio-
therapy for NPC (Lauve et al. 2004; Lu et al. 2004a).
Table 3 Overall Survival and Loco Regional Control of different radio(chemo)therapy regimens for treatment of Nasopharyngeal Carcinoma
Study Patients (n) Treatment RT-dose
(Gy)
Loco Regional
Control
Overall Survival
Present study 26 R(C)T 56–70.4 5 years: 87% 5 years: 74%
Sequent CT, R(C)T and IF
(for undifferentiated NPC)
5 years: 100%
NPC-91-GPOH (Mertens et al. 2005) 59 Sequent CT, RT and IF 59.4 9 years: 91% 9 years: 95%
Chua 1998 (Chua et al. 1998) 335 RT 5 years: 71% 5 years: 42%
C ? RT 66–74 5 years: 78% 5 years: 48%
Ma 2001 (Ma et al. 2001) 456 RT 68–72 5 years: 49% 5 years: 56%
C ? RT 5 years: 59% 5 years: 63%
Dimery 1993 (Dimery et al. 1993)4 7 C ? RT 68–72 6 years: 73% 6 years: 67%
Zhang 2005 (Zhang et al. 2005) 115 RT 70–74 2 years: 83% 2 years: 77%
RCT 2 years: 96% 2 years: 100%
Chan 2005 (Chan et al. 2005) 350 RT 66–76 5 years: 52% 5 years: 59%
RCT 5 years: 62% 5 years: 72%
Wee 2005 (Wee et al. 2005) 189 RT 70 3 years: 53% 3 years: 65%
RCT 3 years: 72% 3 years: 80%
RT radiotherapy; CT chemotherapy; IF interferon-beta, C ? RT neoadjuvant chemotherapy ? radiotherapy; RCT radiochemotherapy; OS overall
survival, DSS disease speciﬁc survival
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123However, this is difﬁcult to achieve in the nasopharyngeal
region due to close critical organs, e.g. optical nerve, chiasm,
and brainstem. Further optimisation and establishment of
recent advantages in radiotherapy may help to apply higher
doses,e.g.bybrachytherapy(Luetal.2004a;N ge ta l .2005),
IMRT (Lu et al. 2004b; Parliament et al. 2005), and stereo-
tactic radiotherapy (Low et al. 2006;W ue ta l .2007).
On the other hand, in the NPC-91-GPOH study,
excellent overall survival—95% after 9 years—and dis-
ease-free survival—91% after 9 years, respectively, could
be obtained with a total radiation dose of 59.4 Gy only
(Mertens et al. 2005). In the current NPC-2003-GPOH
study, a further dose reduction of 54 Gy is intended for
children with complete tumour regression after neoadju-
vant chemotherapy. These encouraging results of the
GPOH studies show that possibly in undifferentiated
nasopharyngeal carcinoma a further dose escalation is not
necessary when adjuvant interferon beta and neoadjuvant
chemotherapy are given, and indicates that both should
also be applied in adult patients, as well as in childhood
NPC. This is of special importance as the lower the
radiation dose the lower the risk for acute and chronic
radiation-induced side effects and the higher the quality
of life for the patients. The question, whether a reduction
of the radiation dose while intensifying systemic therapy
to reduce the risk for radiation-induced side effects
without compromising tumour control is also currently
under investigation in a multicenter phase III study—
Paccis-RCT (Paclitaxel-Cisplatin-Radiochemotherapie)—
of the ‘‘Deutsche Krebshilfe’’ for advanced head and neck
squamous cell carcinoma (oral cavity, oropharynx, hypo-
pharynx, larynx): In this study, the standard arm includes
70.2 Gy irradiation (3 weeks 5 9 2 Gy/week and 3 weeks
2 9 1.4 Gy/day, ﬁve times per week) with additional
5-FU [600 mg/(m
2 TBSA day)] and cisplatin [20 mg/
(m
2 TBSA day)] for 5 days in week 1 and 5 of irradia-
tion. In the experimental arm, radiation dose is reduced to
63.6 Gy (3 weeks 5 9 2 Gy/week and 2.5 weeks 2 9
1.4 Gy/day, ﬁve times per week) plus intensiﬁed con-
comitant chemotherapy (cisplatin 20 mg/(m
2 TBSA day)
for 5 days in week 1 and 5; taxol 25 mg/(m
2 TBSA day)
on day 1, 4, 8, 12, 26, 30, 33, and 37). Aim of the study
is, to test, whether the reduction of the radiation dose with
intensiﬁed chemotherapy results in fewer side effects
without compromising tumour control.
In comparison to other tumour entities of the head and
neck, the NPC is distinctively sensible to radio- and che-
motherapy, and can be cured without surgery in locally
advanced stages at a high percentage (Brennan 2006). One
hypothesis for this fact is the frequent viral association with
Ebstein–Barr virus infection which is reported to be a high
frequent factor in tumour genesis in NPC. For example, Lin
et al. (2004) found a plasma DNA of the EB virus in 94 of
99 patients with NPC but not in 40 healthy or cured patients.
Analogue ﬁndings were reported in other studies (Raab-
Traub 2002; Zhou et al. 2005). Similarly, other tumour
entities, like anal or cervix carcinoma are also well known
to be virus associated and radio(chemo)therapy sensible too
(Bosch et al. 2002; Castellsague 2008; Robinson et al. 2009;
Smith et al. 2007). Furthermore, it was shown that quanti-
ﬁcation of plasma EBV DNA and other serum parameters
like anti-EBV antibodies even allows patient monitoring
with NPC under treatment and can predict outcome and
probability of recurrence (de-Vathaire et al. 1988; Guigay
2008; Lin et al. 2004). Unfortunately, we could not show
this in our analysis due to the fact that EBV parameters
despite the initial EBV-status in the tumour were not col-
lected in our patients. However, we now started to monitor
EBV DNA and serum parameters in all patients treated with
NPC at our department now and in the future. Through this,
further analyses including bio-monitoring and controls in
the course of treatment will be possible.
In summary, our data afﬁrm that NPC in adults are
curable by primary radio(chemo)therapy. Furthermore, our
data indicate that adjuvant interferon-beta application in
undifferentiated NPC in adults is feasible and shows
promising results. Further prospective clinical trials are
needed to ﬁnally establish adjuvant interferon beta in
curative treatment of adult NPC.
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